ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jan 25, 2017
Crisis In Wall Street Stock Research; The Solution? Independent Investment Research
Image Source: Sam Valadi. The dot-com bubble showed how conflicts of interests can sometimes “muddy” the waters when it comes to getting a fair and unbiased opinion on a stock from a Wall Street analyst. Today, a new conflict of interest is brewing. The Wall Street Journal recently reported that sometimes “analysts say ‘buy’ to win special access for their clients” with top executives. Bloomberg followed up the Journal’s article with one of its own. Let’s examine what’s going on.
Jan 25, 2017
Qualcomm in Defense Mode
Image Source: Kārlis Dambrāns. Chip-making giant Qualcomm has found itself firmly in the FTC’s spotlight, and Apple has now piled on with a lawsuit of its own. Let’s take a quick look at the developments.
Jan 24, 2017
Alibaba Group: Still the Quintessential “Play” on China?
Image Shown: Alibaba’s strong free cash flow generation; source: Alibaba. Alibaba has taken a lot of heat from other publishers, but we’ve long liked the company even if it may no longer be a part of the Best Ideas Newsletter portfolio. Some balk at its valuation, but the company’s free cash flow generation and strong balance-sheet net cash position offer substantial legitimacy and support to shares.
Jan 24, 2017
Verizon’s Debt Load Is Too Much and Its Deal with Yahoo Is a Silly Distraction
Image Source: Mike Mozart. Verizon’s financial metrics didn’t stack up during 2016, and management suggested 2017 will be more of the same. We’re cautious on this overleveraged, capital-intensive telecom giant.
Jan 24, 2017
J&J Boasts Below-Market Earnings Multiple; Deal with Actelion Not Concerning
Image Shown: J&J’s robust pharma pipeline; source: J&J.There’s a lot to like about J&J’s investment opportunity, not the least of which is its strong pharmaceutical pipeline. Deal-making could challenge its pristine balance sheet, but we don’t expect much to derail our thesis.
Jan 23, 2017
Have Bristol-Myers Squibb’s Shares Finally Found Support?
Image Source: kennijima. Bristol-Myers Squibb has seen its shares fall to $50 from nearly $80 in just the past few months as clinical outcomes of its crucial product Opdivo have come under fire. Have shares finally found support? Let’s have a look.
Jan 23, 2017
Dividend Increases/Decreases for the Week Ending January 20
Let's take a look at companies raising/lowering their dividends this week.
Jan 23, 2017
Novartis’ Continuous Dividend Growth and Promising Pipeline
Image Shown: Novartis’ dividend history, source: Novartis. Novartis may be in the penalty box, but a healthy dividend growth track record and a promising pipeline may be difficult to overlook. Let’s dig in.
Jan 21, 2017
Calendar Fourth Quarter Earnings Roundup: IBM, GE, PG, UNP
Image Source: texasfeelLet's get our thoughts on calendar fourth-quarter performance from a few giants in their respective industries.
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.